FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North


uPAR (urokinase-type plasminogen activator receptor or urokinase receptor) is part of a proteolytic system and one of the most well-established markers of cancer aggressiveness.

FluoGuide utilizes the fact that cancer cells extensively express the uPAR. FluoGuide has extensive experience within the science field due to the founder Andreas Kjaer has researched for many years in uPAR, imaging and cancer at Rigshospitalet.

uPAR is expressed extracellularly in most types of solid malignancies such as cancer of the breast, prostate, brain and head and neck. It correlates with malignant progression, invasion and metastasis. The uPA/uPAR system is not only an indicator or epiphenomenon but is directly involved in cancer invasion/metastatic processes. Recently a retrospective clinical study was conducted to investigate the target expression and thereby suitability of uPAR for imaging of glioblastoma, breast cancer and head & neck cancer with most encouraging results. uPAR exhibited a tumor-specific expression pattern with low expression in normal tissues outside the tumor compartment. Furthermore, uPAR was expressed at the highest level at the invasive front of the tumor and in tumor-associated stromal cells, making it particularly suitable for delineating the tumor and obtaining negative resection margins with minimally invasive surgery.

The Company currently explores the development of additional products beyond FG001.

Links to published literature

Ploug, M. (2013). Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist. Theranostics, 3(7), 467–476. (link to PubMed)

Kriegbaum, M. C., Persson, M., Haldager, L., Alpizar-Alpizar, W., Jacobsen, B., Gardsvoll, H., Ploug, M. (2011). Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Current Drug Targets, 12(12), 1711–28. (link to PubMed)